Novo Nordisk eyeing upside on US weight loss drug rollout - analysts
Novo Nordisk (NYSE:NVO) could see consensus estimates boosted over the coming years as sales of its weight loss drugs pick up in the US, analysts say. Novo has 12 million patients on its GLP-1-base...
Novo Nordisk continues to impress, says buyer Citi
Novo Nordisk (NYSE:NVO)'s latest results have impressed analysts at Citi, who see little to stop the pharma's value increasing even further as weight control drug Wegovy grows in the US. “While per...
Wegovy maker Novo Nordisk down 4%, heads for worst day since October
Analysts pored over the details in its first-quarter results and monitored a potential rival weight loss treatment.
Novo Nordisk falls after strong Q1 results, Mizuho's Jared Holz talks what's next for the company
Jared Holz, Mizuho, joins 'Fast Money' to talk Novo Nordisk pulling back despite strong quarter.
25,000 people begin taking Wegovy each week, but Novo Nordisk stock is sinking anyway
Danish drugmaker Novo Nordisk, the creator of Ozempic and Wegovy, announced a shocking statistic Thursday: Over 25,000 people begin Wegovy each week. The number is five times larger than the number...
Novo Nordisk A/S (NVO) Q1 2024 Earnings Call Transcript
Novo Nordisk A/S (NVO) Q1 2024 Earnings Conference Call May 2, 2024 7:00 AM ET Company Participants Lars Fruergaard Jørgensen - Chief Executive Officer Camilla Sylvest - Executive Vice President, H...
Novo Nordisk faces competitive market: Novasecta
Subscribe to CNBC International TV: http://cnb.cx/2wAkfMv Subscribe to CNBC International: http://cnb.cx/2gft82z LinkedIn: https://www.linkedin.com/showcase/cnbc-international/ TikTok: https://www....
Novo Nordisk (NVO) Q1 Earnings Beat, GLP-1 Drugs Boost Sales
Novo Nordisk (NVO) reports better-than-expected first-quarter results, beating both earnings and revenues, driven by strong sales of Diabetes and Obesity care products.
Novo Nordisk: Wegovy, Ozempic prices in US fell in Q1
Novo Nordisk has seen the price of its hugely popular weight-loss drug Wegovy and diabetes drug Ozempic fall in the United States as volumes and competition have increased, a senior executive said ...
Novo Nordisk ups guidance after earnings beat expectations
Novo Nordisk (NYSE:NVO), Europe's biggest company, said it is ramping up production of its diabtes/weightloss drugs Wegovy and Ozempic, after patient numbers quadrupled in the US. First-quarter sal...
Novo Nordisk Hikes Guidance as Weight-Loss Drug Sales Surge. Why the Stock's Falling.
The Danish pharmaceutical giant, which became Europe's most valuable company last year, said Wegovy sales jumped 106% in the first quarter.
Ozempic Maker Novo Nordisk Beats Profit Forecasts Amid Weight Loss Drug Frenzy
Danish pharma giant Novo Nordisk raised its 2024 outlook and beat first-quarter profit expectations in its first-quarter earnings report Thursday morning, amid a frenzied rush to match booming cons...
Novo Nordisk now has more than 130,000 weight-loss prescriptions as it hikes financial outlook
Novo Nordisk said its Wegovy injectable drug for weight loss now has more than 130,000 weekly prescriptions in North America alone after boosting supplies to meet insatiable demand.
Earnings report: Novo Nordisk cashes in on weight loss drug fever with better-than-expected results
This morning, pharmaceuticals reported triumphant Q1 2024 financial results before markets opened. One of the more memorable highlights was certainly the fact that Novo Nordisk's sales increased by...
Novo Nordisk beats profit estimates as sales of weight loss drug Wegovy more than double
Sales of popular weight loss drug Wegovy more than doubled to 9.38 billion kroner.
Related Companies